A second controlled-release formulation of the psychostimulant methylphenidate (Ritalin LA) was listed on the Pharmaceutical Benefits Scheme (PBS) on 1 April 2008. The Pharmaceutical Benefits Advisory Committee (PBAC) agreed that Ritalin LA and the previously listed controlled-release formulation (Concerta)
are similarly effective for a similar cost.1
The restricted listing allows Ritalin LA to be prescribed for patients aged 6 to 18 years inclusive for attention deficit hyperactivity disorder (ADHD).1 The patient must have previously responded to the immediate-release
formulation of methylphenidate (Ritalin) without serious adverse events. Relevant State and Territory regulations must also be followed when prescribing psychostimulants.
Immediate-release methylphenidate should be used for initial dose titration before switching to an equivalent dose of
the controlled-release formulation.2 A once-daily dose of Ritalin LA is similar to twice-daily dosing with immediate-release methylphenidate (a once-daily dose of Concerta is equivalent to three-times-daily dosing). Half of the Ritalin LA dose is released immediately
and the other half about 4 hours later, eliminating the need for taking medication at school.3
Reasonable care is taken to provide accurate information at the time of creation. This information is not intended as a substitute for medical advice and should not be exclusively relied on to manage or diagnose a medical condition. NPS MedicineWise disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer. This website uses cookies. Read our privacy policy.
